MX2012001844A - Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis. - Google Patents

Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis.

Info

Publication number
MX2012001844A
MX2012001844A MX2012001844A MX2012001844A MX2012001844A MX 2012001844 A MX2012001844 A MX 2012001844A MX 2012001844 A MX2012001844 A MX 2012001844A MX 2012001844 A MX2012001844 A MX 2012001844A MX 2012001844 A MX2012001844 A MX 2012001844A
Authority
MX
Mexico
Prior art keywords
solid oral
inhibitor
crystalline forms
oral formulations
apoptosis protein
Prior art date
Application number
MX2012001844A
Other languages
English (en)
Inventor
Lili Feng
Jeewan Thakur
Dong Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012001844A publication Critical patent/MX2012001844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a la forma cristalina de la (S)-N-((S)-1 -ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-i lj-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida, a las sales e hidratos de la misma. Esta divulgación también se refiere a una formulación oral sólida de la (S)-N-((S)-1-ciclohexil-2-{(S) -2-[4-(4- fluoro-benzoil)-tiazol-2-il]-pirrolidin-1 -il}-2-oxo-etil)-2-metíl-amino- propionamida, a las sales farmacéuticamente aceptables y solvatos (incluyendo hidratos) de la misma, así como a los métodos para el tratamiento mediante su uso.
MX2012001844A 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis. MX2012001844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Publications (1)

Publication Number Publication Date
MX2012001844A true MX2012001844A (es) 2012-02-29

Family

ID=42937834

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011692A MX351274B (es) 2009-08-12 2010-08-11 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
MX2012001844A MX2012001844A (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013011692A MX351274B (es) 2009-08-12 2010-08-11 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.

Country Status (24)

Country Link
US (4) US8623385B2 (es)
EP (1) EP2464644A1 (es)
JP (3) JP2013501751A (es)
KR (2) KR20120048008A (es)
CN (2) CN102471331B (es)
AR (1) AR077869A1 (es)
AU (4) AU2010283748A1 (es)
BR (1) BR112012003118A2 (es)
CA (1) CA2769616A1 (es)
CL (1) CL2012000349A1 (es)
CO (1) CO6612189A2 (es)
IL (1) IL217760A0 (es)
IN (1) IN2012DN00858A (es)
MA (1) MA33511B1 (es)
MX (2) MX351274B (es)
MY (1) MY160475A (es)
PE (2) PE20121132A1 (es)
PH (1) PH12014501890B1 (es)
RU (1) RU2671196C1 (es)
SG (1) SG177713A1 (es)
TN (1) TN2012000026A1 (es)
TW (1) TWI607006B (es)
WO (1) WO2011018474A1 (es)
ZA (1) ZA201200390B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019514878A (ja) 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124028A1 (en) 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
JP5007235B2 (ja) * 2004-12-20 2012-08-22 ジェネンテック， インコーポレイテッド Ｉａｐのピロリジンインヒビター
PE20110218A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Also Published As

Publication number Publication date
PE20121132A1 (es) 2012-09-04
WO2011018474A8 (en) 2011-09-22
RU2012108931A (ru) 2013-09-27
TWI607006B (zh) 2017-12-01
IN2012DN00858A (es) 2015-07-10
US20120128742A1 (en) 2012-05-24
CA2769616A1 (en) 2011-02-17
KR20120048008A (ko) 2012-05-14
JP2013501751A (ja) 2013-01-17
PH12014501890A1 (en) 2015-09-14
BR112012003118A2 (pt) 2016-02-23
MX351274B (es) 2017-10-06
KR20180020315A (ko) 2018-02-27
SG177713A1 (en) 2012-02-28
PH12014501890B1 (en) 2015-09-14
MA33511B1 (fr) 2012-08-01
JP2016179976A (ja) 2016-10-13
IL217760A0 (en) 2012-03-29
AU2017254950A1 (en) 2017-11-23
US20140093570A1 (en) 2014-04-03
TW201118091A (en) 2011-06-01
CN105646471A (zh) 2016-06-08
JP2018172403A (ja) 2018-11-08
RU2671196C1 (ru) 2018-10-30
US8623385B2 (en) 2014-01-07
US20170081319A1 (en) 2017-03-23
EP2464644A1 (en) 2012-06-20
ZA201200390B (en) 2012-10-31
CL2012000349A1 (es) 2012-09-07
AR077869A1 (es) 2011-09-28
PE20170777A1 (es) 2017-07-04
US20180370960A1 (en) 2018-12-27
AU2010283748A1 (en) 2012-02-09
WO2011018474A1 (en) 2011-02-17
CO6612189A2 (es) 2013-02-01
US10093665B2 (en) 2018-10-09
AU2017254950B2 (en) 2018-09-20
US9540363B2 (en) 2017-01-10
MY160475A (en) 2017-03-15
TN2012000026A1 (en) 2013-09-19
AU2016203145A1 (en) 2016-06-02
AU2014213533A1 (en) 2014-09-04
CN102471331A (zh) 2012-05-23
CN102471331B (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
EP2477625A4 (en) PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY157017A (en) Sulfonamide derivatives
PH12014500053A1 (en) Proteasome inhibitors
MX2011003473A (es) Composiciones para el cuidado bucal.
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
TN2010000203A1 (en) Beta-lactamase inhibitors
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
IN2012DN03310A (es)
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011011109A (es) Formulaciones orales de bendamustina.
UA99787C2 (en) Lactams as beta secretase inhibitors
TN2010000299A1 (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropy-ran-4-yl)-propionamide
MX2010005307A (es) Derivados heterociclicos como moduladores de canales de iones.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis

Legal Events

Date Code Title Description
FG Grant or registration